 Andrew Getahun
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| B-Lymphocytes | 27 | 2026 | 870 | 3.570 |
Why?
| | Clonal Anergy | 9 | 2026 | 52 | 2.480 |
Why?
| | Receptors, Antigen, B-Cell | 8 | 2026 | 130 | 1.920 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2026 | 382 | 1.650 |
Why?
| | Antibody Formation | 9 | 2018 | 288 | 1.560 |
Why?
| | B-Lymphocyte Subsets | 5 | 2019 | 76 | 1.470 |
Why?
| | Signal Transduction | 17 | 2026 | 5216 | 1.390 |
Why?
| | Autoimmune Diseases | 4 | 2022 | 468 | 1.120 |
Why?
| | src-Family Kinases | 4 | 2026 | 92 | 1.060 |
Why?
| | Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 6 | 2026 | 15 | 1.050 |
Why?
| | PTEN Phosphohydrolase | 5 | 2019 | 165 | 0.930 |
Why?
| | Lymphocyte Activation | 9 | 2022 | 1132 | 0.900 |
Why?
| | T-Lymphocytes | 5 | 2024 | 1996 | 0.770 |
Why?
| | Immunoglobulins | 4 | 2023 | 162 | 0.750 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 3 | 2026 | 10 | 0.750 |
Why?
| | Mice, Transgenic | 14 | 2026 | 2188 | 0.670 |
Why?
| | Mice | 37 | 2026 | 18329 | 0.650 |
Why?
| | Immunoglobulin G | 8 | 2015 | 892 | 0.640 |
Why?
| | Bites and Stings | 1 | 2020 | 30 | 0.610 |
Why?
| | Autoimmunity | 9 | 2025 | 933 | 0.600 |
Why?
| | Adjuvants, Immunologic | 3 | 2005 | 243 | 0.590 |
Why?
| | Immune Tolerance | 5 | 2022 | 385 | 0.580 |
Why?
| | Membrane Proteins | 3 | 2025 | 1164 | 0.550 |
Why?
| | Animals | 45 | 2026 | 38030 | 0.550 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2019 | 238 | 0.520 |
Why?
| | Macrophages | 2 | 2025 | 1507 | 0.480 |
Why?
| | Spleen | 7 | 2020 | 508 | 0.470 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2020 | 145 | 0.470 |
Why?
| | Amino Acid Motifs | 2 | 2015 | 219 | 0.460 |
Why?
| | Antigens | 2 | 2009 | 348 | 0.460 |
Why?
| | Phosphoric Monoester Hydrolases | 4 | 2020 | 56 | 0.450 |
Why?
| | Receptors, Fc | 1 | 2015 | 54 | 0.440 |
Why?
| | Genotype | 1 | 2020 | 1852 | 0.430 |
Why?
| | Immunoglobulin E | 4 | 2015 | 315 | 0.430 |
Why?
| | Virus Diseases | 1 | 2017 | 216 | 0.420 |
Why?
| | Receptors, IgG | 4 | 2015 | 77 | 0.400 |
Why?
| | Mice, Inbred C57BL | 14 | 2026 | 5983 | 0.380 |
Why?
| | Gammaherpesvirinae | 1 | 2012 | 45 | 0.360 |
Why?
| | Mice, Knockout | 16 | 2025 | 3124 | 0.350 |
Why?
| | Down-Regulation | 2 | 2024 | 618 | 0.350 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2025 | 1140 | 0.340 |
Why?
| | Autoantigens | 2 | 2015 | 427 | 0.340 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 148 | 0.340 |
Why?
| | Nitrohydroxyiodophenylacetate | 1 | 2009 | 3 | 0.310 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 340 | 0.300 |
Why?
| | Nucleotides, Cyclic | 2 | 2020 | 22 | 0.300 |
Why?
| | Autoantibodies | 6 | 2025 | 1509 | 0.290 |
Why?
| | Antibodies, Viral | 1 | 2012 | 674 | 0.270 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2023 | 919 | 0.260 |
Why?
| | Immunoglobulin M | 4 | 2015 | 265 | 0.260 |
Why?
| | Epitopes | 1 | 2009 | 473 | 0.260 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2005 | 174 | 0.260 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 3 | 2019 | 100 | 0.250 |
Why?
| | Interleukin-4 | 3 | 2019 | 207 | 0.240 |
Why?
| | Antibodies | 3 | 2015 | 397 | 0.240 |
Why?
| | Antigen Presentation | 2 | 2005 | 207 | 0.240 |
Why?
| | Immunoglobulin mu-Chains | 2 | 2011 | 8 | 0.240 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2025 | 13 | 0.230 |
Why?
| | Antigens, CD | 3 | 2020 | 558 | 0.230 |
Why?
| | Lymphocytes | 2 | 2025 | 376 | 0.230 |
Why?
| | Receptors, IgE | 1 | 2005 | 43 | 0.230 |
Why?
| | T-Lymphocyte Subsets | 2 | 2019 | 418 | 0.220 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2025 | 25 | 0.220 |
Why?
| | CD79 Antigens | 2 | 2014 | 16 | 0.190 |
Why?
| | Immunotherapy | 2 | 2019 | 666 | 0.190 |
Why?
| | Ligands | 3 | 2023 | 665 | 0.180 |
Why?
| | Berylliosis | 1 | 2025 | 202 | 0.180 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2004 | 364 | 0.180 |
Why?
| | Mice, Inbred BALB C | 5 | 2011 | 1261 | 0.180 |
Why?
| | Adoptive Transfer | 6 | 2015 | 200 | 0.180 |
Why?
| | Allergens | 1 | 2025 | 386 | 0.180 |
Why?
| | Immunologic Memory | 2 | 2021 | 368 | 0.180 |
Why?
| | Gene Knock-In Techniques | 2 | 2020 | 61 | 0.180 |
Why?
| | Interleukin-27 | 1 | 2021 | 13 | 0.170 |
Why?
| | Vaccines, Subunit | 1 | 2021 | 53 | 0.170 |
Why?
| | Up-Regulation | 1 | 2004 | 847 | 0.170 |
Why?
| | Costimulatory and Inhibitory T-Cell Receptors | 1 | 2020 | 7 | 0.160 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2021 | 132 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2025 | 4560 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2025 | 1217 | 0.160 |
Why?
| | Receptors, Complement 3d | 2 | 2012 | 129 | 0.160 |
Why?
| | src Homology Domains | 2 | 2020 | 35 | 0.150 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 480 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1124 | 0.150 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2019 | 25 | 0.150 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 108 | 0.140 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 2018 | 7 | 0.140 |
Why?
| | Fishes | 1 | 1999 | 109 | 0.140 |
Why?
| | HLA-DP beta-Chains | 1 | 2019 | 88 | 0.140 |
Why?
| | Mice, 129 Strain | 3 | 2014 | 84 | 0.140 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2018 | 41 | 0.140 |
Why?
| | DNA | 1 | 2025 | 1435 | 0.140 |
Why?
| | Alarmins | 1 | 2018 | 27 | 0.140 |
Why?
| | Sheep | 2 | 2012 | 876 | 0.140 |
Why?
| | Cellular Reprogramming Techniques | 1 | 2018 | 10 | 0.140 |
Why?
| | Antigens, Bacterial | 1 | 2018 | 126 | 0.130 |
Why?
| | Recombination, Genetic | 1 | 2018 | 203 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 167 | 0.130 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 1505 | 0.130 |
Why?
| | Polymorphism, Genetic | 1 | 2020 | 614 | 0.130 |
Why?
| | Alleles | 1 | 2020 | 894 | 0.120 |
Why?
| | Erythrocytes | 4 | 2012 | 748 | 0.120 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 91 | 0.120 |
Why?
| | Lymphocyte Count | 3 | 2021 | 164 | 0.120 |
Why?
| | Lung Injury | 1 | 2019 | 244 | 0.120 |
Why?
| | Immunoglobulin Class Switching | 1 | 2015 | 21 | 0.120 |
Why?
| | MicroRNAs | 2 | 2019 | 686 | 0.110 |
Why?
| | Humans | 17 | 2025 | 145474 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2015 | 133 | 0.110 |
Why?
| | Immunomodulation | 1 | 2015 | 99 | 0.110 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2014 | 26 | 0.100 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2015 | 167 | 0.100 |
Why?
| | Germinal Center | 3 | 2015 | 64 | 0.100 |
Why?
| | Cytokines | 2 | 2019 | 2067 | 0.100 |
Why?
| | Mice, Inbred NOD | 3 | 2022 | 613 | 0.100 |
Why?
| | Plasma Cells | 1 | 2014 | 79 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2022 | 3922 | 0.100 |
Why?
| | Lung | 2 | 2025 | 4106 | 0.100 |
Why?
| | Protein Binding | 2 | 2020 | 2238 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2023 | 334 | 0.100 |
Why?
| | Asthma | 1 | 2025 | 1797 | 0.100 |
Why?
| | Antigens, Ly | 1 | 2013 | 45 | 0.100 |
Why?
| | Listeriosis | 1 | 2013 | 63 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 477 | 0.090 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 208 | 0.090 |
Why?
| | Complement Pathway, Classical | 1 | 2011 | 17 | 0.090 |
Why?
| | Mast Cells | 1 | 2013 | 147 | 0.090 |
Why?
| | Immunophenotyping | 1 | 2012 | 319 | 0.080 |
Why?
| | Beryllium | 2 | 2025 | 161 | 0.080 |
Why?
| | Cell Line | 3 | 2018 | 2823 | 0.080 |
Why?
| | Inflammation | 2 | 2019 | 2878 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2019 | 2046 | 0.080 |
Why?
| | Models, Immunological | 2 | 2010 | 99 | 0.080 |
Why?
| | Monocytes | 1 | 2013 | 539 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2018 | 2597 | 0.070 |
Why?
| | Acute Disease | 1 | 2012 | 1036 | 0.070 |
Why?
| | Ovalbumin | 2 | 2009 | 194 | 0.070 |
Why?
| | Proteins | 1 | 2015 | 1023 | 0.070 |
Why?
| | Receptors, Complement | 1 | 2009 | 123 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 328 | 0.070 |
Why?
| | Complement System Proteins | 1 | 2011 | 314 | 0.070 |
Why?
| | Cell Movement | 1 | 2013 | 959 | 0.070 |
Why?
| | Cells, Cultured | 5 | 2015 | 4148 | 0.070 |
Why?
| | Phosphorylation | 3 | 2020 | 1707 | 0.060 |
Why?
| | Immunization, Secondary | 2 | 2004 | 92 | 0.060 |
Why?
| | Female | 9 | 2025 | 78844 | 0.060 |
Why?
| | Janus Kinases | 1 | 2025 | 21 | 0.060 |
Why?
| | Trinitrobenzenes | 1 | 2005 | 14 | 0.060 |
Why?
| | Toll-Like Receptor 7 | 1 | 2025 | 43 | 0.060 |
Why?
| | STAT Transcription Factors | 1 | 2025 | 25 | 0.060 |
Why?
| | Mice, Congenic | 1 | 2005 | 23 | 0.060 |
Why?
| | Alternaria | 1 | 2025 | 9 | 0.060 |
Why?
| | Haptens | 1 | 2005 | 25 | 0.060 |
Why?
| | Antigen-Antibody Complex | 1 | 2005 | 69 | 0.060 |
Why?
| | Receptors, CXCR5 | 1 | 2025 | 27 | 0.050 |
Why?
| | Lymphocyte Depletion | 2 | 2016 | 132 | 0.050 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 439 | 0.050 |
Why?
| | Phosphoproteins | 2 | 2020 | 337 | 0.050 |
Why?
| | Mice, Inbred CBA | 1 | 2004 | 57 | 0.050 |
Why?
| | Hypersensitivity, Delayed | 1 | 2004 | 29 | 0.050 |
Why?
| | Inositol Polyphosphate 5-Phosphatases | 2 | 2015 | 4 | 0.050 |
Why?
| | Male | 6 | 2025 | 72842 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 848 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2025 | 499 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1041 | 0.050 |
Why?
| | Immunoglobulin Light Chains | 1 | 2022 | 52 | 0.050 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2022 | 86 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 118 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 312 | 0.040 |
Why?
| | Immunization | 2 | 2014 | 375 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2018 | 1162 | 0.040 |
Why?
| | Receptors, Virus | 1 | 2021 | 95 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 129 | 0.040 |
Why?
| | Catfishes | 1 | 1999 | 7 | 0.040 |
Why?
| | Culture Techniques | 1 | 1999 | 66 | 0.040 |
Why?
| | Tertiary Lymphoid Structures | 1 | 2019 | 7 | 0.040 |
Why?
| | Chemokine CXCL13 | 1 | 2019 | 15 | 0.040 |
Why?
| | Protein Structure, Quaternary | 1 | 1999 | 116 | 0.040 |
Why?
| | Lymphopenia | 1 | 2019 | 62 | 0.040 |
Why?
| | Haploinsufficiency | 1 | 2019 | 54 | 0.040 |
Why?
| | Macromolecular Substances | 1 | 1999 | 216 | 0.040 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 331 | 0.040 |
Why?
| | Immunity, Innate | 1 | 2025 | 835 | 0.040 |
Why?
| | Phenotype | 2 | 2019 | 3155 | 0.040 |
Why?
| | Granuloma | 1 | 2019 | 97 | 0.040 |
Why?
| | Chronic Disease | 1 | 2025 | 1808 | 0.040 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2019 | 119 | 0.030 |
Why?
| | Chemokines | 1 | 2019 | 217 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 1999 | 563 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2019 | 167 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 1999 | 372 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| | Immunoglobulin D | 1 | 2015 | 29 | 0.030 |
Why?
| | Rituximab | 1 | 2016 | 210 | 0.030 |
Why?
| | Cytidine Deaminase | 1 | 2015 | 59 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 247 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 3542 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2018 | 273 | 0.030 |
Why?
| | Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2014 | 9 | 0.030 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 21 | 0.030 |
Why?
| | Lectins | 1 | 2014 | 44 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 397 | 0.030 |
Why?
| | Mice, Inbred DBA | 1 | 2014 | 182 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 440 | 0.020 |
Why?
| | Vaccination | 1 | 2021 | 1426 | 0.020 |
Why?
| | Dendritic Cells, Follicular | 1 | 2012 | 5 | 0.020 |
Why?
| | Fibroblasts | 1 | 2018 | 1025 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 459 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 977 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2014 | 372 | 0.020 |
Why?
| | Chromatography, Agarose | 1 | 2011 | 3 | 0.020 |
Why?
| | Serum Amyloid P-Component | 1 | 2011 | 3 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 37 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1179 | 0.020 |
Why?
| | Gene Targeting | 1 | 2011 | 81 | 0.020 |
Why?
| | RNA | 1 | 2018 | 910 | 0.020 |
Why?
| | Insulin | 1 | 2022 | 2512 | 0.020 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 431 | 0.020 |
Why?
| | Tyrosine | 1 | 2011 | 217 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 505 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2011 | 319 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2013 | 361 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2011 | 335 | 0.020 |
Why?
| | Gene Expression | 1 | 2014 | 1476 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2011 | 422 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 447 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2006 | 80 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1480 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1896 | 0.010 |
Why?
| | Hemolytic Plaque Technique | 1 | 2001 | 28 | 0.010 |
Why?
| | Immunization, Passive | 1 | 2001 | 90 | 0.010 |
Why?
| | Feedback | 1 | 2001 | 180 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1048 | 0.010 |
Why?
| | Kinetics | 1 | 2001 | 1567 | 0.010 |
Why?
|
|
Getahun's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|